Endo Unit Shutdown Could Strand Incontinence Treatment Praised By FDA Panel
This article was originally published in The Gray Sheet
Endo International plans to shutter its Astora Women's Health business unit – formerly part of American Medical Systems – this month due to ongoing legal concerns tied to the company’s vaginal mesh products. What’s unclear is what this means for the company’s investigational fecal incontinence treatment, which received unanimous support from an FDA advisory panel just days before the shutdown was announced.
You may also be interested in...
Some plaintiffs in ongoing multi-district litigation against pelvic mesh manufacturer American Medical Systems were recruited to the case by cold-callers and did not need to have the mesh removed, the company argued in a recent court filing.
All members of the agency's Gastroenterology and Urology Devices Panel were convinced by Astora Women’s Health's evidence in support of PMA approval for the TOPAS mesh implant device for fecal incontinence.
FDA issued final orders up-classifying surgical mesh for transvaginal repair of pelvic organ prolapse from class II to class III and calling for PMA standards, including clinical trial, animal studies, and materials testing data from new and existing manufacturers.